Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chihoko Takahata"'
Autor:
Haruru Kotani, Mitsuo Terada, Makiko Mori, Nanae Horisawa, Kayoko Sugino, Ayumi Kataoka, Yayoi Adachi, Naomi Gondou, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Chihoko Takahata, Makiko Kobara, Hiroji Iwata
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using surgical gloves
Externí odkaz:
https://doaj.org/article/7fe3ed73cb8d44a5909cf60cb8fec0fb
Autor:
Haruru Kotani, Mitsuo Terada, Makiko Mori, Nanae Horisawa, Kayoko Sugino, Ayumi Kataoka, Yayoi Adachi, Naomi Gondou, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Chihoko Takahata, Makiko Kobara, Hiroji Iwata
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using surgical gloves. On acc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0668f873cb6d2ba33967f447d8d291f8
https://doi.org/10.21203/rs.3.rs-77419/v1
https://doi.org/10.21203/rs.3.rs-77419/v1
Autor:
Nanae Horisawa, Hiroji Iwata, Makiko Mori, Masataka Sawaki, Ayumi Kataoka, Mitsuo Terada, Masaya Hattori, Chihoko Takahata, Akiyo Yoshimura, Kayoko Sugino, N Gondou, Haruru Kotani, Makiko Kobara, Yayoi Adachi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of paclitaxel (PTX). There is no known prophylactic measure, although there are some reports of prevention with compression therapy using surgical gloves. On acco
Autor:
Koji Kurihara, Chihoko Takahata, Akimitsu Maeda, Kazuhide Inaguma, Makiko Kobara, Yasunari Mizuno, Kazuhiro Shimomura, Kaori Hara
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 43:713-718
Autor:
Eri Hotta, Kazuhiro Shimomura, Kyoko Kato, Hiroya Taniguchi, Masahiro Tajika, Yukiya Narita, Toshiki Masuishi, Kei Muro, Makiko Kobara, Shigenori Kadowaki, Naoya Hashimoto, Sachiyo Onishi, Chihoko Takahata, Seiichiro Mitani, Shinji Takahashi
Publikováno v:
The Oncologist
Lessons Learned A shortened infusion of ramucirumab (from 60 to 20 minutes) was safe and feasible without infusion-related reactions. Twenty-minute infusions of ramucirumab can be an option for patients with no infusion-related reactions during the f